WO2015148880A1 - Method for the preparation of n-acetyl cysteine amide - Google Patents
Method for the preparation of n-acetyl cysteine amide Download PDFInfo
- Publication number
- WO2015148880A1 WO2015148880A1 PCT/US2015/022910 US2015022910W WO2015148880A1 WO 2015148880 A1 WO2015148880 A1 WO 2015148880A1 US 2015022910 W US2015022910 W US 2015022910W WO 2015148880 A1 WO2015148880 A1 WO 2015148880A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acetyl
- cysteine
- organic
- acid
- reduced pressure
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 title abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 9
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- -1 N-acetyl-L-cysteine ester Chemical class 0.000 claims description 10
- 229910021529 ammonia Inorganic materials 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002274 desiccant Substances 0.000 claims description 6
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 6
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 6
- 239000011736 potassium bicarbonate Substances 0.000 claims description 6
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical group [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 239000000908 ammonium hydroxide Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229960004592 isopropanol Drugs 0.000 claims description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 125000005233 alkylalcohol group Chemical group 0.000 claims 2
- 241001669680 Dormitator maculatus Species 0.000 description 13
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960001563 acetylcysteine amide Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
- C07C319/12—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols by reactions not involving the formation of mercapto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
Definitions
- GSH glutathione
- NACA N-acetyl cysteine amide
- NACA /V-acetyl cysteine amide
- This disclosure describes an efficient method or process for the preparation of NACA in high chemical yields and high enantiomeric purity. Specifically, disclosed herein is a process comprising:
- NACA /V-acetyl-L- cysteine amide
- the alcohol is selected from the group consisting of methanol, ethanol, propanol, iso-propanol and butanol.
- the alcohol is methanol.
- the acid is selected from the group consisting of sulfuric acid, hydrochloric acid and phosphoric acid or a combination thereof. In one particular aspect, the acid is sulfuric acid.
- the base is selected from the group consisting of sodium bicarbonate, sodium hydrogen carbonate, potassium bicarbonate, potassium hydrogen carbonate, lithium carbonate or a combination thereof.
- the base is sodium bicarbonate.
- the step c) further comprises adding an organic solvent to the neutralized mixture.
- the organic solvent is selected from the group consisting of ethyl acetate, tetrahydrofuran, methylethylketone and dichloromethane.
- the organic solvent is ethyl acetate.
- the step c) comprises drying the organic solution with a drying agent.
- the drying agent is anhydrous sodium sulfate.
- the ammonia is aqueous ammonium hydroxide.
- the step of contacting of the /V-acetyl-L-cysteine ester with ammonia is performed at room temperature.
- the step d) of removing the organics under reduced pressure is performed at about 45 °C.
- removal of the organics may be performed at about 45 °C or less, 40 °C or less or 35 °C or less.
- the separated organic solution in step c) is further filtered to remove solids.
- the process provides NACA in about 70% yield, about 75% yield, about 85% yield or about 95% yield or more. In another aspect, the process provides NACA in greater than 90% enatiomeric excess (e.e.), 95% e.e, 97% e.e., 98% e.e., or greater than 99% e.e. as determined by optical rotation in methanol.
- the alcohol is selected from the group consisting of methanol, ethanol, propanol, iso-propanol and butanol. In another aspect, the alcohol is methanol.
- the acid is selected from the group consisting of sulfuric acid, hydrochloric acid and phosphoric acid or a combination thereof.
- the acid is sulfuric acid.
- the base is selected from the group consisting of sodium bicarbonate, sodium hydrogen carbonate, potassium bicarbonate, potassium hydrogen carbonate, lithium carbonate or a combination thereof.
- the base is sodium bicarbonate.
- step c) the process further comprising adding an organic solvent to the neutralized mixture.
- the organic solvent is selected from the group consisting of ethyl acetate, tetrahydrofuran, methylethylketone and dichloromethane.
- the organic solvent is ethyl acetate.
- the process comprises drying the organic solution with a drying agent.
- the drying agent is anhydrous sodium sulfate.
- the ammonia is aqueous ammonium hydroxide.
- the contacting of the /V-acetyl-L-cysteine ester with ammonia is performed at room temperature.
- the step d) of removing the organics under reduced pressure is performed at about 45 °C.
- removal of the organics may be performed at about 45 °C or less, 40 °C or less or 35 °C or less.
- the separated organic solution in step c) is further filtered to remove solids.
- the process provides NACA in about 70% yield or greater.
- the solid was recrystallized from hot ethanol to give an off-white solid (102 g) m.p. 139 - 143 °C.
- the 1 NMR showed primarily the desired product together with -4-5% of disulfide of /V-acetyl-L-cysteine amide (di-NACA) as impurity.
- the crude solid was further purified on combi-flash silica gel column using 1 -10% methanol-dichloromethane gradient to afford high-grade NACA product (62 g) as a colorless crystalline solid; (m.p. 147-151 °C; Lit. m.p. 148-150 °C).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Polymers & Plastics (AREA)
Abstract
The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.
Description
METHOD FOR THE PREPARATION OF N-ACETYL CYSTEINE AMIDE
BACKGROUND OF THE APPLICATION
[0001] Decreased glutathione (GSH) availability in the brain is linked to several neurodegenerative diseases including Parkinson's disease. Means of restoring GSH levels include delivery of GSH precursors, e.g. / -acetyl cysteine, /V-acetyl cysteine amide (NACA) or cysteine to the brain. However, directly administered, these GSH precursors have limited therapeutic usefulness because of their limited bioavailability.
[0002] The preparation of /V-acetyl cysteine amide (NACA) has been previously described in J. Med. Chem. 1967, 10, 1 172-1 176.
[0003] There is a need for developing an efficient method for the effective, large scale synthesis of N-acetyl cysteine amide that provides the product in high chemical yields and high chemical and enantiomeric purity.
SUMMARY OF THE APPLICATION
[0004] This disclosure describes an efficient method or process for the preparation of NACA in high chemical yields and high enantiomeric purity. Specifically, disclosed herein is a process comprising:
- contacting N-acetyl-L-cysteine with an organic alcohol and an inorganic acid to form an organic solution containing N-acetyl-L-cysteine ester;
- neutralizing the acid in the organic solution with an aqueous solution containing a base to form a neutralized mixture;
- separating an organic solution containing N-acetyl-L-cysteine ester from the neutralized mixture;
- removing the N-acetyl-L-cysteine ester from the organic solution under reduced pressure; and
- contacting the N-acetyl-L-cysteine ester with ammonia.
[0005] In one embodiment, there is provided a process for the preparation of /V-acetyl-L- cysteine amide (NACA) comprising:
a) contacting /V-acetyl-L-cysteine with an alcohol and an acid under condition sufficient to form an organic solution containing N-acetyl-L-cysteine ester;
b) neutralizing the acid in the organic solution with an aqueous solution containing a base to form a neutralized mixture;
c) separating the organic solution containing /V-acetyl-L-cysteine ester from the aqueous solution;
d) removing the organics under reduced pressure to provide the /V-acetyl-L-cysteine
ester; and e) contacting the /V-acetyl-L-cysteine ester with ammonia under conditions sufficient to form NACA.
[0006] In one aspect of the above embodiment, the alcohol is selected from the group consisting of methanol, ethanol, propanol, iso-propanol and butanol. In another aspect, the alcohol is methanol. In another aspect of the process, the acid is selected from the group consisting of sulfuric acid, hydrochloric acid and phosphoric acid or a combination thereof. In one particular aspect, the acid is sulfuric acid.
[0007] In another embodiment of the above process, the base is selected from the group consisting of sodium bicarbonate, sodium hydrogen carbonate, potassium bicarbonate, potassium hydrogen carbonate, lithium carbonate or a combination thereof. In one particular aspect, the base is sodium bicarbonate.
[0008] In another aspect of any of the above embodiments and aspects, the step c) further comprises adding an organic solvent to the neutralized mixture. In another aspect, the organic solvent is selected from the group consisting of ethyl acetate, tetrahydrofuran, methylethylketone and dichloromethane. In one aspect, the organic solvent is ethyl acetate.
[0009] In yet another aspect of the above process, the step c) comprises drying the organic solution with a drying agent. In one aspect of the above, the drying agent is anhydrous sodium sulfate. In yet another aspect of the process, the ammonia is aqueous ammonium hydroxide.
[0010] In another aspect of any of the above embodiments and aspects, the step of contacting of the /V-acetyl-L-cysteine ester with ammonia is performed at room temperature. In another aspect, the step d) of removing the organics under reduced pressure is performed at about 45 °C. In one variation, removal of the organics may be performed at about 45 °C or less, 40 °C or less or 35 °C or less. In another aspect of the process, the separated organic solution in step c) is further filtered to remove solids.
[0011] In another aspect of the above embodiments and aspects, the process provides NACA in about 70% yield, about 75% yield, about 85% yield or about 95% yield or more. In another aspect, the process provides NACA in greater than 90% enatiomeric excess (e.e.), 95% e.e, 97% e.e., 98% e.e., or greater than 99% e.e. as determined by optical rotation in methanol.
[0012] In one aspect of the process, the alcohol is selected from the group consisting of methanol, ethanol, propanol, iso-propanol and butanol. In another aspect, the alcohol is methanol.
[0013] In another aspect of the process, the acid is selected from the group consisting of sulfuric acid, hydrochloric acid and phosphoric acid or a combination thereof. In another
aspect, the acid is sulfuric acid. In another aspect, the base is selected from the group consisting of sodium bicarbonate, sodium hydrogen carbonate, potassium bicarbonate, potassium hydrogen carbonate, lithium carbonate or a combination thereof. In another aspect, the base is sodium bicarbonate.
[0014] In another aspect of the process, in step c), the process further comprising adding an organic solvent to the neutralized mixture. In another aspect, the organic solvent is selected from the group consisting of ethyl acetate, tetrahydrofuran, methylethylketone and dichloromethane. In one particular aspect, the organic solvent is ethyl acetate.
[0015] In yet another aspect of the process, in step c), the process comprises drying the organic solution with a drying agent. In another aspect, the drying agent is anhydrous sodium sulfate. In yet another aspect, the ammonia is aqueous ammonium hydroxide.
[0016] In another aspect of the process, the contacting of the /V-acetyl-L-cysteine ester with ammonia is performed at room temperature. In another aspect of the process, the step d) of removing the organics under reduced pressure is performed at about 45 °C. In one variation, removal of the organics may be performed at about 45 °C or less, 40 °C or less or 35 °C or less. In another aspect of the process, the separated organic solution in step c) is further filtered to remove solids. In yet another aspect, the process provides NACA in about 70% yield or greater.
DETAILED DESCRIPTION OF THE APPLICATION EXPERIMENTS:
[0017] The following procedures may be employed for the preparation of the compound of the present invention. The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as the Aldrich Chemical Company (Milwaukee, Wis.), Bachem (Torrance, Calif.), Sigma (St. Louis, Mo.), or are prepared by methods well known to a person of ordinary skill in the art, following procedures described in such references as Fieser and Fieser's Reagents for Organic Synthesis, vols. 1 -17, John Wiley and Sons, New York, N.Y., 1991 ; Rodd's Chemistry of Carbon
Compounds, vols. 1 -5 and supps., Elsevier Science Publishers, 1989; Organic Reactions, vols. 1 -40, John Wiley and Sons, New York, N.Y., 1991 ; March J.: Advanced Organic Chemistry, 4th ed., John Wiley and Sons, New York, N.Y.; and Larock: Comprehensive Organic Transformations, VCH Publishers, New York, 1989.
[0019] /V-Acetyl Cysteine Methyl Ester:
[0020] A suspension of /V-acetyl-L-cysteine (32.6 g) in dry methanol (120 mL) under nitrogen was stirred for 15 minutes and treated dropwise with concentrated sulfuric acid (0.8 mL) at room temperature with vigorous stirring. After 22 hours of stirring, the mixture was treated with water (25 mL) and the volatiles were removed under reduced pressure. The resulting residue was diluted with ethyl acetate (200 mL), washed with aqueous saturated sodium bicarbonate (150 mL) and the layers were allowed to separate.
[0021] The organic layer was separated from the aqueous layer and dried over anhydrous sodium sulfate. The aqueous layer was re-extracted with ethyl acetate (2 x 100 mL). The combined organic extract was filtered and concentrated in vacuo to yield /V-Acetyl- L-cysteine methyl ester (24.1 g, 68%) as a white crystalline solid: 1H NMR (400 MHz DMSO- cfe) δ (ppm): 8.29 (d, 1 H), 4.39 (m, 1 H), 3.60 (s, 3H), 2.77 (dd, 1 H), 2.70 (dd, 1 H), 2.51 (s, 1 H), 1.84 (s, 3H); LRMS: 178.13 (M+H)+.
[0022] Scale-up Preparation of /V-Acetyl Cysteine Methyl Ester: To a suspension of N- acetyl-L-cysteine (162.7 g) in dry methanol (600 mL) under nitrogen was added
concentrated H2SO4 (4 mL) drop-wise at room temperature with vigorous stirring. After 24 hours of stirring, the mixture was slowly treated with saturated aqueous sodium bicarbonate solution (100 mL) and stirred for 1 hour.
[0023] The solvent was removed under reduced pressure, and the resulting aqueous portion was extracted with dicholoromethane (4 x 100 mL), dried over anhydrous sodium sulfate, concentrated and vacuum-dried to afford the desired methyl ester product as an off- white solid (12
[0024] /V-Acetyl-L-Cysteine Amide (NACA):
[0025] /V-Acetyl-L-cysteine methyl ester (10 g) under a flush of nitrogen was treated with ammonium hydroxide (28% aqueous, 66 mL) over 10 minutes at room temperature and stirred for 6 hours. The resulting solution was concentrated in vacuo and ethanol (100 mL) was added. The resulting solution was concentrated again under reduced pressure at 48 °C,
then subjected to high vacuum overnight to afford /V-acetyl-L-cysteine amide (NACA, 9.12 g) as a white crystalline solid (m.p. 138 - 141 °C; Lit. 148 - 150 °C); 1H NMR (400 MHz DMSO- cfe) δ (ppm): 7.89 (d, 1 H), 7.30 (s, 1 H), 7.01 (s, 1 H), 4.16 (m, 1 H), 2.64 (dd, 1 H), 2.52 (dd, 1 H), 1.74 (s, 3H); LRMS 163.13 (M+H)+.
[0026] Alternative preparation of NACA. To /V-Acetyl cysteine methyl ester (120 g, 0.67 mol) under nitrogen was added ammonium hydroxide solution (750 mL) at room
temperature. After stirring at room temperature under N2 atmosphere for 24 hours, the excess ammonia was removed under reduced pressure. The rest of the reaction solution was azeotroped with ethanol (600 mL) at 48 °C under reduced pressure leaving a solid product which was dried under high vacuum overnight.
[0027] The solid was recrystallized from hot ethanol to give an off-white solid (102 g) m.p. 139 - 143 °C. The 1NMR showed primarily the desired product together with -4-5% of disulfide of /V-acetyl-L-cysteine amide (di-NACA) as impurity. The crude solid was further purified on combi-flash silica gel column using 1 -10% methanol-dichloromethane gradient to afford high-grade NACA product (62 g) as a colorless crystalline solid; (m.p. 147-151 °C; Lit. m.p. 148-150 °C).
[0028] While a number of exemplary embodiments, aspects and variations have been provided herein, those of skill in the art will recognize certain modifications, permutations, additions and combinations and certain sub-combinations of the embodiments, aspects and variations. It is intended that the following claims are interpreted to include all such modifications, permutations, additions and combinations and certain sub-combinations of the embodiments, aspects and variations are within their scope. The entire disclosures of all documents cited throughout this application are incorporated herein by reference.
Claims
1 . A process comprising:
contacting N-acetyl-L-cysteine with an organic alcohol and an inorganic acid to form an organic solution containing N-acetyl-L-cysteine ester;
neutralizing the acid in the organic solution with an aqueous solution containing a base to form a neutralized mixture;
separating an organic solution containing N-acetyl-L-cysteine ester from the neutralized mixture;
removing the N-acetyl-L-cysteine ester from the organic solution under reduced pressure; and
contacting the N-acetyl-L-cysteine ester with ammonia.
2. The process of claim 1 , wherein the organic alcohol is an alkyl alcohol.
3. The process of claim 2, wherein the alkyl alcohol is methanol, ethanol, propanol, iso- propanol or butanol.
4. The process of claim 2, wherein the alcohol is methanol.
5. The process of claim 1 , wherein the inorganic acid is sulfuric acid, hydrochloric acid, phosphoric acid, or a combination thereof.
6. The process of claim 5, wherein the acid is sulfuric acid.
7. The process of any one of claims 1 to 5, wherein the base is sodium bicarbonate, sodium hydrogen carbonate, potassium bicarbonate, potassium hydrogen carbonate, lithium carbonate or a combination thereof.
8. The process of claim 6, wherein the base is sodium bicarbonate.
9. The process of any one of claims 1 to 7, step c), further comprising adding an organic solvent to the neutralized mixture.
10. The process of claim 9, wherein the organic solvent is ethyl acetate, tetrahydrofuran, methylethylketone or dichloromethane.
1 1. The process of claim 9, wherein the organic solvent is ethyl acetate.
12. The process of any one of claims 1 to 10, further comprising drying the organic solution removed from the neutralized mixture with a drying agent.
13. The process of claim 12, wherein the drying agent is anhydrous sodium sulfate.
14. The process of any one of claims 1 to 13, wherein the ammonia is provide in the form of aqueous ammonium hydroxide.
15. The process of any one of claims 1 to 14, wherein the contacting of the N-acetyl-L- cysteine ester with ammonia is performed at room temperature.
16. The process of any one of claims 1 to 15, wherein the removing the organics under reduced pressure is performed at about 45 °C or less.
17. The process of any one of claims 1 to 15, wherein the removing the organics under reduced pressure is performed at about 35 °C or less.
18. The process of any one of claims 1 to 15, wherein the removing the organics under reduced pressure is performed at about 30 °C or less.
19. The process of any one of claims 1 to 15, wherein the removing the organics under reduced pressure is performed at about 45 °C.
20. The process of any one of claims 1 to 19, wherein the organic solution removed from the neutralized mixture is filtered to remove solids.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/300,092 US9763902B2 (en) | 2014-03-28 | 2015-03-27 | Method for preparation of N-acetyl cysteine amide |
EP15770142.6A EP3122342B1 (en) | 2014-03-28 | 2015-03-27 | Method for the preparation of n-acetyl cysteine amide |
US15/696,912 US9889103B2 (en) | 2014-03-28 | 2017-09-06 | Method for the preparation of N-acetyl cysteine amide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461972133P | 2014-03-28 | 2014-03-28 | |
US61/972,133 | 2014-03-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/300,092 A-371-Of-International US9763902B2 (en) | 2014-03-28 | 2015-03-27 | Method for preparation of N-acetyl cysteine amide |
US15/696,912 Continuation US9889103B2 (en) | 2014-03-28 | 2017-09-06 | Method for the preparation of N-acetyl cysteine amide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015148880A1 true WO2015148880A1 (en) | 2015-10-01 |
Family
ID=54196427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/022910 WO2015148880A1 (en) | 2014-03-28 | 2015-03-27 | Method for the preparation of n-acetyl cysteine amide |
Country Status (3)
Country | Link |
---|---|
US (2) | US9763902B2 (en) |
EP (1) | EP3122342B1 (en) |
WO (1) | WO2015148880A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019060623A1 (en) * | 2017-09-20 | 2019-03-28 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
US11268964B2 (en) | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
US11753370B2 (en) | 2017-11-09 | 2023-09-12 | Nacuity Pharmaceuticals, Inc. | Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stress |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420429B1 (en) * | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
WO2004012652A2 (en) * | 2002-08-02 | 2004-02-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8709547D0 (en) * | 1987-04-22 | 1987-05-28 | Lilly Industries Ltd | Organic compounds |
-
2015
- 2015-03-27 WO PCT/US2015/022910 patent/WO2015148880A1/en active Application Filing
- 2015-03-27 US US15/300,092 patent/US9763902B2/en active Active
- 2015-03-27 EP EP15770142.6A patent/EP3122342B1/en active Active
-
2017
- 2017-09-06 US US15/696,912 patent/US9889103B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420429B1 (en) * | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
WO2004012652A2 (en) * | 2002-08-02 | 2004-02-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
Non-Patent Citations (2)
Title |
---|
"SUPELCO. Methanolic H2SO4. 1997 Sigma-Aldrich Co.", TYPICAL PROCEDURE, pages 1, XP055228012, Retrieved from the Internet <URL:https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Supelco/Product_Information_Sheet/4786.pdf> [retrieved on 20150523] * |
See also references of EP3122342A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11268964B2 (en) | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
WO2019060623A1 (en) * | 2017-09-20 | 2019-03-28 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
US10590073B2 (en) | 2017-09-20 | 2020-03-17 | Nacuity Pharmaceuticals, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
AU2020233602B2 (en) * | 2017-09-20 | 2022-07-07 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
US11753370B2 (en) | 2017-11-09 | 2023-09-12 | Nacuity Pharmaceuticals, Inc. | Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stress |
Also Published As
Publication number | Publication date |
---|---|
EP3122342B1 (en) | 2020-09-23 |
EP3122342A4 (en) | 2017-11-22 |
US9763902B2 (en) | 2017-09-19 |
EP3122342A1 (en) | 2017-02-01 |
US20170183302A1 (en) | 2017-06-29 |
US9889103B2 (en) | 2018-02-13 |
US20170368009A1 (en) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9889103B2 (en) | Method for the preparation of N-acetyl cysteine amide | |
US9771364B2 (en) | Process for preparation of (2S,5R)-6-sulphooxy-7-oxo-2-[((3R)-piperidine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane | |
KR102430612B1 (en) | Preparation of piperidine-4-carbothioamide | |
US9630909B2 (en) | Process for the preparation of nepafenac | |
KR20160061542A (en) | A Novel Method for Separation of Luliconazole Isomers | |
JP2012020970A (en) | Method for producing {3-(1-diphenylmethylazetidin-3-yl)ester-5-isopropyl ester 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate} | |
US20140186252A1 (en) | Ammonia borane purification method | |
KR100881890B1 (en) | Process for preparation of Sarpogrelate HCl salt | |
JP4356111B2 (en) | Process for producing N- (2-amino-1,2-dicyanovinyl) formamidine | |
JP6660393B2 (en) | Method for preparing 4-cyanopiperidine hydrochloride | |
TWI565696B (en) | 2-Amino-6-methylnicotinic acid | |
JP6239458B2 (en) | Process for producing 2- (benzylsulfinyl) -1-cycloalkene-1-carboxylic acid ester | |
JP6042153B2 (en) | Olanzapine production method | |
JP2011132224A (en) | Method for producing 5-(aminomethyl)-2-chlorothiazole | |
WO2015087291A1 (en) | 3-carboxy-4-(r)-phenylpyrrolydine-2-one salt and its use | |
US20160244425A1 (en) | A process for the preparation of olopatadine and sylil intermediates thereof | |
JP2005187461A (en) | Method for producing primary amine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15770142 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15300092 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2015770142 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015770142 Country of ref document: EP |